Why is this study being conducted?
This research study is testing a potential new treatment for Idiopathic Pulmonary Fibrosis (IPF). The purpose of this research study is to evaluate the effectiveness, safety, and tolerability of the study drug when given intravenously (through a vein usually in the arm) in participants with IPF.
Who is eligible to participate in this study?
You may be eligible if you:
- Are 40 years of age or older
- Have a diagnosis of Idiopathic Pulmonary Fibrosis
Applicants who express interest in participating in this study will be reviewed and contacted as other requirement criteria must also be met.
What happens during the study?
Trial duration will be about 11 months and you will have about 19 trial visits.
Trial site visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
You will be assigned randomly by chance (like the flip of a coin) to receive Axatilimab or placebo.
Contact Jessica Todd
To learn more about this clinical trial, please contact:
Jessica Todd, Clinical Trial Coordinator.
0401 119 059 clinicaltrialunit@griffith.edu.au
This study has been approved by Bellberry Human Research Ethics Committee #2022-08-815 and GU HREC #2024/732.
Can't see a trial for you?
Join our volunteer database to be contacted about new clinical trials